Curis, Inc. (NasdaqGM:CRIS) Stock Price & Quote Analysis

CRIS Stock Overview

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.

CRIS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 19.76% per year

Risk Analysis

Earnings are forecast to decline by an average of 8.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

+ 1 more risk

My Notes

New

Notes are coming soon

Curis, Inc. Competitors

Ambrx Biopharma

NYSE:AMAM

US$69.5m

Kineta

NasdaqCM:KA

US$77.0m

Adagene

NasdaqGM:ADAG

US$81.6m

Aziyo Biologics

NasdaqCM:AZYO

US$80.0m

Price History & Performance

Summary of all time highs, changes and price drops for Curis
Historical stock prices
Current Share Price	US$0.78
52 Week High	US$3.76
52 Week Low	US$0.47
Beta	2.87
1 Month Change	27.87%
3 Month Change	-0.40%
1 Year Change	-74.84%
3 Year Change	-46.58%
5 Year Change	-69.92%
Change since IPO	-99.36%

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Jan 02

Recent updates

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Jan 02

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Sep 16

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Feb 17

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

Dec 23

Curis prices equity offering at $5.75/share

Dec 09

Curis skyrockets 141% on encouraging CA-4948 data in leukemia

Dec 08

What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Dec 03

Curis, National Cancer Institute in development pact for anti-cancer agent

Nov 11

Shareholder Returns

	CRIS	US Biotechs	US Market
7D	0.06%	-0.8%	1.7%
1Y	-74.8%	4.4%	-9.6%

Return vs Industry: CRIS underperformed the US Biotechs industry which returned 4.5% over the past year.

Return vs Market: CRIS underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is CRIS's price volatile compared to industry and market?
CRIS volatility
CRIS Average Weekly Movement	12.3%
Biotechs Industry Average Movement	12.1%
Market Average Movement	6.7%
10% most volatile stocks in US Market	17.5%
10% least volatile stocks in US Market	2.8%

Stable Share Price: CRIS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: CRIS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2000	60	Jim Dentzer	https://www.curis.com

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate.

Curis, Inc. Fundamentals Summary

How do Curis's earnings and revenue compare to its market cap?
CRIS fundamental statistics
Market Cap	US$75.19m
Earnings (TTM)	-US$58.96m
Revenue (TTM)	US$10.41m

7.2x

P/S Ratio

-1.3x

P/E Ratio

Is CRIS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRIS income statement (TTM)
Revenue	US$10.41m
Cost of Revenue	US$35.98m
Gross Profit	-US$25.57m
Other Expenses	US$33.39m
Earnings	-US$58.96m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.61
Gross Margin	-245.63%
Net Profit Margin	-566.41%
Debt/Equity Ratio	0%

How did CRIS perform over the long term?

See historical performance and comparison

CRIS Stock Overview

Rewards

Risk Analysis

Curis, Inc. Competitors

NYSE:AMAM

US$69.5m

NasdaqCM:KA

US$77.0m

NasdaqGM:ADAG

US$81.6m

NasdaqCM:AZYO

US$80.0m

Price History & Performance

Recent News & Updates

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Price target increased to US$15.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.25

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Recent updates

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Price target increased to US$15.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.25

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Price target increased to US$17.67

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis: Asymmetric Risk And Reward

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Consensus EPS estimates fall by 14%

Price target increased to US$15.75

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$14.20

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors

Checking In On Curis

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Curis Inc.: Revisiting CA-4948 After Q2 Update

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2020)

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.28 loss in 1Q 2020)

Curis Receives U.S. Food and Drug Administration Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Full year 2020 earnings released: US$0.61 loss per share (vs US$0.97 loss in FY 2019)

Curis, Inc. to Report Q4, 2020 Results on Mar 16, 2021

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Curis Announces Initiation of Investigator-Sponsored Phase 2 Lucas Study of Ca-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

New 90-day high: US$9.32

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

New 90-day high: US$8.20

Curis, Inc. has completed a Follow-on Equity Offering in the amount of $147.500001 million.

Curis, Inc. Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Curis prices equity offering at $5.75/share

Curis skyrockets 141% on encouraging CA-4948 data in leukemia

What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition